CME Credits:
Credits for Specialists: This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada, and approved by Queen’s University.

Learning Objectives:

− To understand and address, through clinical and translational research, the disease burden associated with head and neck malignancies in Canada.
− To review recent developments in the understanding of molecular biology and new therapeutics as these relate to head and neck malignancies.
− To update, review, and discuss recent results of clinical studies conducted by or in collaboration with Canadian Cancer Trials Group.
− To provide mentoring opportunities for investigators new to clinical trial research.
− To understand and apply new clinical trial methodologies in the field of clinical research related to head and neck malignancies.

8:00 am Welcome

CCTG approved trials

8:05 am HN.10 - A Phase II Single Arm Trial of Elective Volume Adjusted De- Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal Squamous Cell Carcinoma. S. Bratman

9:00 am HN.9 - Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA- OSCC). K Sultanem/A Spreafico

9:30 am HN.6 Secondary Analyses Update W Parulekar, J Ringash, J Waldron, L Siu, R Martino

9:45 am CCTG/ NRG/ HNIG (Head and Neck International Group) Interactions J Waldron

10:00 am Innovative Surgical Techniques and Clinical Trials A Nichols

10:30 am Opportunities for Surgical Research in CCTG Head and Neck Cancer Disease Site Committee

11:30 am New Proposals

12:00 pm Meeting Adjourned